



## UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS  
 UNITED STATES PATENT AND TRADEMARK OFFICE  
 WASHINGTON, D.C. 20231  
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/922,067	08/03/2001	Colin Houston MacPhee	P30693C4C1

20462  
 SMITHKLINE BEECHAM CORPORATION  
 CORPORATE INTELLECTUAL PROPERTY-US, UW2220  
 P. O. BOX 1539  
 KING OF PRUSSIA, PA 19406-0939

CONFIRMATION NO. 8753

## FORMALITIES LETTER



\*OC000000007120083\*

Date Mailed: 11/26/2001

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
 CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
 DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH  
THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-  
CLASS MAIL IN AN ENVELOPE ADDRESSED TO:

ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231,  
ON December 18, 2001

*Audrey Boyd*  
December 18, 2001  
DATE

*610300 #5:*

*O I P E JCS 9  
JAN 23 2002  
PATENT & TRADEMARK OFFICE*

Attorney Docket No.: P30693C4X1C1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MacPhee, et al. 18 December 2001  
Serial No.: 09/922,067 Group Art Unit No.: 1645  
Filed: August 3, 2001 Examiner: Not Yet Assigned  
For: Lipoprotein Associated Phospholipase A2 Inhibitors Thereof and Use of  
the Same in Diagnosis and Therapy

**STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE  
WITH 37 CFR §§ 1.821 THROUGH 1.825**

**BOX SEQUENCE**

Assistant Commissioner for Patents  
Washington, D.C. 20231

( X ) I hereby state that the contents of the paper and computer readable copies of  
the Sequence Listing, submitted in accordance with **37 CFR §1.821(c)** and **(e)**,  
respectively, are the same.

( ) I hereby state that the submission filed in accordance with **37 CFR §1.821 (g)**  
does not include new matter.

( ) I hereby state that the submission filed in accordance with **37 CFR §1.821 (h)**  
does not include new matter or go beyond the disclosure in the international  
application as filed.

( ) I hereby state that the amendments, made in accordance with **37 CFR §1.825**  
**(a)**, included in the substitute sheet(s) of the Sequence Listing are supported in  
the application, as filed, at pages \_\_\_\_\_. I hereby state that the substitute  
sheet(s) of the Sequence Listing does (do) not include new matter.

( ) I hereby state that the substitute copy of the computer readable form,  
submitted in accordance with **37 CFR §1.825(b)**, is the same as the amended  
Sequence Listing.

Serial No.: 09/922,067  
Group Art Unit No.: 1645

( ) I hereby state that the substitute copy of the computer readable form, submitted in accordance with **37 CFR §1.825(d)**, is identical to that originally filed.

Respectfully submitted,



William T. Han  
Attorney for Applicants  
Registration No. 34,344

GLAXOSMITHKLINE  
Corporate Intellectual Property - UW2220  
P.O. Box 1539  
King of Prussia, PA 19406-0939  
Phone (610) 270-5219  
Facsimile (610) 270-5090

N:\HAN\APPS\P30693-C4\P30693C4C1statsupp.doc